secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001493152-25-001516
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics enters ATM sales agreement for up to $1.2M with B. Riley Securities
--------------------------------------------------------------------------------

- Amendment No. 1 to At Market Issuance Sales Agreement with B. Riley Securities, dated Jan 9, 2025.
- Company may sell up to $1.2 million of common stock from time to time in at-the-market offerings.
- Agent commission is 3.0% of gross sales price; Company can terminate agreement on notice.
- Sales will be made under effective shelf registration statement (333-280244), declared effective Jan 8, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315225001516/0001493152-25-001516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315225001516/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer